A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

Lee, Je‐Hwan; Joo, Young-Don; Kim, Hawk; Bae, Sung Hwa; Kim, Min Kyoung; Zang, Dae Young; Lee, Junglim; Lee, Gyeong Won; Lee, Jung‐Hee; Park, Jae-Hoo; Kim, Dae-Young; Lee, Won-Sik; Ryoo, Hun Mo; Hyun, Myung Soo; Kim, Hyo Jung; Min, Young Joo; Jang, Yae-Eun; Lee, Kyoo‐Hyung

doi:10.1182/blood-2011-06-361410

Cited by 133 publications

(85 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefit of HD daunorubicin has since been confirmed prospectively in both younger 28 and older patients, 29 as well as by a retrospective meta-analysis. 30 The celebration of the original results was tempered by the determination that not all subgroups benefited; in particular, patients with high-risk features such as older age (age $50 years), unfavorable cytogenetics, and FLT3-ITD mutant AML did not appear to derive benefit.…”

Section: Discussionmentioning

confidence: 99%

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Luskin

Lee

Fernandez

et al. 2016

Blood

112

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Luskin

Lee

Fernandez

et al. 2016

Blood

112

View full text Add to dashboard Cite

show abstract

“…Randomized studies have indicated that daunorubicin at 45 mg/m 2 daily 33 is associated with a lower CR rate and a higher relapse rate than 90 mg/m 2 daily 33 when daunorubicin is used in a single induction cycle. [139][140][141] This clear dose-effect relation seems much less prominent in patients .65 years of age. However, another comparison found that 90 mg/m 2 daunorubicin daily 33 in a first induction cycle was not superior to daunorubicin at 60 mg/m 2 daily 33.…”

Section: 2138mentioning

confidence: 96%

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner

Estey

Grimwade

et al. 2017

Blood

4,685

5,387

View full text Add to dashboard Cite

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease

show abstract

“…However, cumulative data suggests that IDA, which has a longer intracellular retention time, used at a dose of 12 mg/m 2 for 3 days, has comparable remission rates with fewer additional therapies [12,13,14]. In China, an inadequate dose of IDA often results in an unsatisfactory efficacy.…”

Section: Discussionmentioning

confidence: 99%

Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison

et al. 2014

View full text Add to dashboard Cite

Objectives: The aims of this study were to evaluate a novel induction regimen composed of idarubicin (IDA), cytarabine (Ara-C) and cladribine (IAC regimen) for acute myeloid leukemia (AML) patients, and to identify the prognostic factors affecting treatment outcomes. Methods: The clinical data of 27 untreated AML patients who received the IAC regimen as primary induction therapy in our hospital between April and November 2014 were analyzed retrospectively. The treatment outcomes of the IAC regimen were compared with two IA (IDA + Ara-C) regimens (IDA 10 mg/m² and IDA 12 mg/m²) in a pair-matched analysis. Results: The complete remission (CR) rate in the IAC arm was higher compared to the IA^L arm (p = 0.002) as was the overall efficacy rate (p = 0.017). There was no significant difference in outcomes between the IAC and IA^H (Ara-C with high-dose IDA) arms. The IAC arm contained significantly higher CR rates than the IA^L (Ara-C with low-dose IDA) arm in both the intermediate group (p = 0.050) and the unfavorable group (p = 0.013). Toxicity did not differ between the IAC group and the other two arms. High WBC at diagnosis (p = 0.022) and an unfavorable karyotype (p = 0.026) were related to a poorer response. The IAC regimen (p = 0.013) had greater superiority over the IA^L regimen on efficacy than over the IA^H regimen (p = 0.041). Conclusions: The IAC regimen achieved a more significant advantage over the IA^L regimen without increasing the risk of adverse events. The efficacy of induction therapy is associated with WBC at diagnosis, karyotype and induction regimen.

show abstract

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

Cited by 133 publications

References 24 publications

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison

Contact Info

Product

Resources

About